 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Moderna, Inc. (MRNA), a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases.
As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation; and a research collaboration with Harvard University.
Moderna, Inc. also has a collaboration with Lonza Ltd. for the manufacture of mRNA-1273, a COVID-19 vaccine. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018.
Moderna reported a 1st Quarter March 2020 loss of $0.35 per share on revenue of $8.4 million. The consensus estimate was a loss of $0.37 per share on revenue of $18.2 million. Revenue fell 47.7% compared to the same quarter a year ago.
Dr. Fauci is positive in the company's chances in developing the vaccine for COVID-19. Please see our blog for more information and listen to Dr. Fauci's comments.
Entry point: $53.00
52-week trade range: $11.54 - $56.38
Stop/Loss: $50.35
Target Price: $58.30
Taking profit at $64.00. Please note, this stock may be heading higher.
